KCI's Prevena Becomes First FDA-Cleared Negative Pressure Wound-Closure Device
Executive Summary
The US FDA granted KCI's de novo request for the Prevena incision management system, making it the first negative pressure device cleared for reducing superficial surgical site infections in patients at high risk.
You may also be interested in...
3M Aims For Acelity In $6.7Bn Deal To Expand Wound-Care Presence
3M is betting big on wound-care maker Acelity and paying $6.7bn to buy the company and its KCI subsidiaries in its largest acquisition to date.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.